Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904139 | 0.89 | DDB1 (0.31) | ARSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20714805 | 0.81 | AR (0.49) | ARSMN1; SMN2MEN1KMT2AMAOA | |
| SCHEMBL4912458 | 0.81 | FBP1 (0.33) | — | |
| SCHEMBL14154715 | 0.76 | MAPT (0.39) | ARSMN1; SMN2MEN1KMT2AMAOA | |
| SCHEMBL4908425 | 0.73 | DDB1 (0.39) | SMN1; SMN2 | |
| SCHEMBL576770 | 0.71 | MAPT (0.46) | SMN1; SMN2 | |
| SCHEMBL4899169 | 0.70 | DDB1 (0.35) | — | |
| SCHEMBL1146608 | 0.69 | SLC6A4 (0.38) | SMN1; SMN2MEN1KMT2AMAOARECQL | |
| SCHEMBL14113988 | 0.68 | TXN (0.37) | RECQL | |
| SCHEMBL19121747 | 0.67 | SKP2 (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949480-B2 | N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150327547-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-19 | — | — | US | disclosed |
| US-9096635-B2 | N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096635-B2 | N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140235565-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235565-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-21 | — | — | US | disclosed |
| US-8722937-B2 | Asymmetric disulfides and aryl-alkyl disulfides as anti-bacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | SQOR, TST, COASY | AR 1320/4885SMN1; SMN2 1758/4885MEN1 4682/4885 |
| US-20150327547-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | COASY, SQOR, TST | AR 1493/4885SMN1; SMN2 2837/4885MEN1 4526/4885 |
| US-20140235565-A1 | N-ALKYLTHIO BETA-LACTAMS, ALKYL-COENZYME A ASYMMETRIC DISULFIDES, AND ARYL-ALKYL DISULFIDES AS ANTI-BACTERIAL AGENTS | COASY, SQOR, TST | AR 1493/4885SMN1; SMN2 2837/4885MEN1 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.